Adenocarcinoma Contains More Immune Tolerance Regu

Authors: Candice C Black Mary Jo Turk Konstantin Dragnev James R Rigas

Publish Date: 2013/03/15

Volume: 191, Issue: 3, Pages: 265-270

PDF Link

Abstract

Regulatory T lymphocytes Tregs are known to have hostimmune dampening effects in many tumors and to be associated with increased tumor recurrence Pharmacologic therapies have been developed to target these cells and hence strengthen the host’s immune system The FoxP3 gene is a marker of Tregs and can be visualized with immunohistochemistry IHC We investigated the presence and pattern of Tregs in nonsmallcell lung tumors to determine possible therapeutic targets in lung cancerWe selected archival samples of primary lung carcinoma and benign inflamed lung from 32 surgical resections We created a tissue array containing duplicate cores from the N1 and N2 nodal stations from 16 of the cases along with paired benign lung and tumor We used wholeslide analysis for the other 16 cases We used FoxP3 IHC to visualize Tregs in all lymphoid tissue present and to assess the quantity and pattern within the tissuesAll lymphoid tissue contains Tregs but adenocarcinoma had significantly higher levels than both inflammatory lung controls and squamous carcinomas p ≤ 0008 Benign N1 lymph nodes from patients with lung cancer showed higher numbers of Tregs for adenocarcinoma versus squamous carcinomaThese findings reveal that Tregs are present in all lung tissues examined but with significant enrichment in adenocarcinoma This may lead to a more permissive microenvironment for adenocarcinoma and may explain aggressive patterns of tumor spread for this histology Lung cancer patients with adenocarcinoma histology may benefit most from Tregtargeted therapy

Keywords: